ARCHIVE

• Maintaining Double-digit Growth Rates: Mr Matsumoto of J&J
  February 24, 2003

• Meiji Seika: Results Coming from New Infectious Disease Research Laboratories
  February 24, 2003

• Yamanouchi Grants InductOs Promotion Right in Europe to Medtronic
  February 24, 2003

• Reform Council to Work with CEFP to Further Healthcare Regulatory Reform
  February 24, 2003

• SSP Initiates Clinical Study on Antibacterial Eye Drops in US
  February 24, 2003

• Sankyo, Fujisawa to Market Aventis' Telithromycin
  February 24, 2003

• Testing Conditions Announced for 23rd Quality Reevaluation
  February 24, 2003

• JSC Recommends Discontinuation of Intradermal Test for Antibacterials
  February 24, 2003

• Kyowa Hakko Sets Up Antibody Biz House
  February 24, 2003

• Physicians with Knowledge of Both Western and Oriental Medicine Needed: Kampo Symposium
  February 24, 2003

• Eli Lilly Conducts Trial on Switching from Typical to Atypical Antipsychotic Drugs
  February 24, 2003

• Pharma SNP Consortium to Complete Activities in May
  February 24, 2003

• Singulair's Share Up Since Approval of Long-term Prescription: Banyu
  February 24, 2003

• PRESS SEMINAR
  February 24, 2003

• Novo Nordisk Pharma to Focus Harder on Diabetes: President Moore
  February 24, 2003

• RESEARCH & DEVELOPMENT NEWS IN BRIEF
  February 24, 2003

• Sales of Anti-allergic Talion Set to Double in FY2002: Tanabe
  February 24, 2003

• Dr Calfee Points Out Lack of Freedom Hits Drug Industry in Germany, Japan: PhRMA Seminar
  February 17, 2003

• MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
  February 17, 2003

• Dainippon Wishes to Sharply Recover from Next Fiscal Year
  February 17, 2003

ページ

• « 先頭
• ‹ Prev
• …
• 617
• 618
• 619
• 620
• 621
• 622
• 623
• 624
• 625
• …
• Next ›
• 最終 »